CELL INTELLIGENCE · 肿瘤细胞治疗研究

T 细胞动力学、CD8/NK 比值及肿瘤生存特征决定骨髓瘤对 T 细胞双特异性抗体 forimtamig 的应答

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

多发性骨髓瘤 CAR-T 细胞治疗的全球趋势：2013-2025 年文献计量学分析

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025.

多发性骨髓瘤中 T 细胞重定向治疗的皮肤毒性：EADV 工作组立场文件与实践建议

Cutaneous Toxicities of T-Cell-Redirecting Therapies in Multiple Myeloma: An EADV Task Force Position Paper and Practical Recommendations.

天然味觉调节剂与微生物组导向营养支持用于免疫治疗相关味觉障碍：精准肿瘤支持治疗的转化视角

Natural Taste Modulators and Microbiome-Aware Nutritional Support for Immunotherapy-Associated Dysgeusia: A Translational Perspective for Precision Su

用于多发性骨髓瘤中 BCMA/GPRC5D 共转导 CAR-T 细胞实验室规模制备的可规模化慢病毒工作流程

A Scalable Lentiviral Workflow for Laboratory-Scale Generation of BCMA/GPRC5D Co-Transduced CAR-T Cells in Multiple Myeloma.

多发性骨髓瘤中 BCMA 和 GPRC5D 靶向 CAR-T 细胞治疗应答的患者特异性决定因素：基于临床试验与真实世界数据的 QSP 分析

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Re

接受 BiTEs 和 CAR-T 细胞治疗的多发性骨髓瘤感染风险的真实世界证据：一项荟萃分析

Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.

在真实世界实践中，接受 T 细胞重定向治疗的 RRMM 患者中约每 4 例就有 1 例发生严重感染。

多发性骨髓瘤免疫治疗序贯的真实世界证据：既往 GPRC5D 靶向治疗后 BCMA 靶向双特异性抗体可带来持久缓解

Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5

靶向 BCMA 的双特异性抗体为经靶向 GPRC5D 的双特异性抗体治疗后进展的患者提供了一种有效且耐受性良好的治疗选择，支持该序贯方案作为一种有前景策略的可行性。

多发性骨髓瘤中抗 BCMA CAR-T 细胞治疗前桥接治疗的经验与专家小组共识

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma.

多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸

Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.